Live Breaking News & Updates on Analyst Recommendations For Catalyst Pharmaceuticals

Stay updated with breaking news from Analyst recommendations for catalyst pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded to Buy by StockNews.com

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Friday. Several other analysts also recently commented on CPRX. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a […] ....

United-states , America , Gary-ingenito , Brian-elsbernd , Dekabank-deutsche-girozentrale , Catalyst-pharmaceuticals , Analyst-recommendations-for-catalyst-pharmaceuticals , Catalyst-pharmaceuticals-company-profile , Citigroup , Catalyst-pharmaceuticals-inc , Securities-exchange-commission , Cantor-fitzgerald

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of "Buy" by Brokerages

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of "Buy" by Brokerages
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states , America , Davids-tierney , Catalyst-pharmaceuticals-inc , News-ratings-for-catalyst-pharmaceuticals-daily , Parkside-financial-bank , Sherbrooke-park-advisers , Catalyst-pharmaceuticals-company-profile , Catalyst-pharmaceuticals , Tower-research-capital , Catalyst-pharmaceuticals-price-performance

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $26.43 Average Price Target from Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $26.43 Average Price Target from Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states , America , Davids-tierney , Catalyst-pharmaceuticals-inc , News-ratings-for-catalyst-pharmaceuticals-daily , Parkside-financial-bank , Sherbrooke-park-advisers , Catalyst-pharmaceuticals-company-profile , Catalyst-pharmaceuticals , Tower-research-capital , Catalyst-pharmaceuticals-stock-performance

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Rating of "Buy" from Brokerages

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) have received an average recommendation of “Buy” from the five brokerages that are covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the […] ....

United-states , Brian-elsbernd , Institutional-trading-of-catalyst-pharmaceuticals , Catalyst-pharmaceuticals-inc , Citigroup , News-ratings-for-catalyst-pharmaceuticals-daily , Covestor-ltd , Catalyst-pharmaceuticals , Securities-exchange-commission , Parkside-financial-bank , Advisory-services-network , Analyst-recommendations-for-catalyst-pharmaceuticals

Catalyst Pharmaceuticals (NASDAQ:CPRX) Given "Outperform" Rating at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) in a research report report published on Wednesday, Benzinga reports. They currently have a $29.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on the company. Citigroup began coverage on Catalyst […] ....

United-states , America , Brian-elsbernd , Parkside-financial-bank , News-ratings-for-catalyst-pharmaceuticals-daily , Covestor-ltd , Catalyst-pharmaceuticals , Securities-exchange-commission , Catalyst-pharmaceuticals-stock-performance , Catalyst-pharmaceuticals-inc , Citigroup , Cantor-fitzgerald